Results 1 to 10 of about 202 (68)
Piloting a forced-choice task to elicit treatment preferences in geographic atrophy [PDF]
BMC Research Notes, 2023 Objective Geographic Atrophy (GA) is the advanced form of the non-neovascular (‘dry’) type of age-related macular degeneration (AMD) and responsible for one-quarter of legal blindness in the UK.
Jamie Enoch +5 more
doaj +3 more sources
Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review [PDF]
Ophthalmology and TherapyRationale In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration.
Anne Helene Køllund Nissen +2 more
doaj +3 more sources
Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol [PDF]
Clinical OphthalmologyRyan B Rush,1– 3 Westin Klein,1 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology, Southwest ...
Rush RB, Klein W, Reinauer RM
doaj +4 more sources
One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy [PDF]
Clinical OphthalmologyRyan B Rush,1– 3 Westin Klein,1 Sloan W Rush,1,2 Robert Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology ...
Rush RB, Klein W, Rush SW, Reinauer R
doaj +4 more sources
Geographic atrophy: pathophysiology and current therapeutic strategies [PDF]
Frontiers in Ophthalmology, 2023 Geographic atrophy (GA) is an advanced stage of age-related macular degeneration (AMD) that leads to gradual and permanent vision loss. GA is characterized by the loss of photoreceptor cells and retinal pigment epithelium (RPE), leading to distinct ...
Kalpana Rajanala +2 more
doaj +2 more sources
Visual Function Assessment in Geographic Atrophy: A Review. [PDF]
Clin Exp OphthalmolABSTRACT Geographic atrophy (GA) causes significant vision impairment and reduction in vision‐related quality of life. Fundus autofluorescence (FAF) is the gold standard of structural assessment of GA but is a surrogate marker for vision loss, which can be assessed by tests of visual function and functional vision.
Li Y, Ayton LN, Fung AT.
europepmc +2 more sources
Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy [PDF]
Clinical OphthalmologyRyan B Rush,1– 3 Westin Klein,1,3 Sloan W Rush,1,2 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of ...
Rush RB, Klein W, Rush SW, Reinauer RM
doaj +2 more sources
Avacincaptad Pegol: First Approval
, 2023 Declarations Funding The preparation of this review was not supported by any external funding. Authorship and Conflict of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the ...
Connie Kang (7248215)
core +1 more source
Treatment of dry age‐related macular degeneration: A review
Clinical &Experimental Ophthalmology, Volume 51, Issue 8, Page 835-852, November 2023., 2023 Abstract Age‐related macular degeneration is a global disease with a significant societal impact. The advent of anti‐vascular endothelial growth factor therapy (anti‐VEGF) has revolutionised the treatment of neovascular age‐related macular degeneration (nAMD).
Shenouda Girgis, Lawrence R. Lee
wiley +1 more source
Advanced Science, Volume 13, Issue 2, 9 January 2026.The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen +5 more
wiley +1 more source